Request Trial
nudelman-herceptin
19 September 2023FeaturesPharmaTakanori Abe

Regimen patents in Japan: LCM failures and successes

Regimen patenting is part of the lifecycle management (LCM) strategy of originator companies. The following is an overview of LCM failures and successes in regimen patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.
Pharma
USPTO director steps into Sun Pharma’s PTAB-ITC clash
31 July 2026   A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026

More features

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
Fran Salisbury: ‘There’s nothing quite like finding the missing piece’
Patent litigator joins Baker Botts in London as UPC grows in significance
USPTO director steps into Sun Pharma’s PTAB-ITC clash
Where Big Pharma is betting big in the M&A boom
Buying the brains: Why is Big Pharma shopping for innovation?
Trump slaps 100% tariff on generic drugs in US manufacturing push